Investigational drug · Phase 3
WD-890
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "WD-890"
First trial start
2024
Dec 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WD-890", any sponsor or status.
Conditions studied
As listed on its trial records.
- Brief Description of Focus of Study
- Moderate to Severe Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "WD-890" as an intervention, largest first.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Zhejiang Wenda Pharma Technology LTD.Industry
NCT07672561 · 375 participants (planned) · Start Mar 18, 2026 · Primary completion Nov 30, 2026
Drug: Drug:WD-890; Drug: placebo · For: Moderate to Severe Plaque Psoriasis
Sites: Nanjing, China
- A Study of WD-890 in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingRecruiting
Zhejiang Wenda Pharma Technology LTD.Industry
NCT06912165 · 140 participants (planned) · Start Dec 31, 2024 · Primary completion Oct 30, 2025
Drug: WD-890 tablet; WD-890 tablet and 2 more · For: Brief Description of Focus of Study
Sites: Nanjing, China
- A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese SubjectsPivotal-lookingCompleted
Zhejiang Wenda Pharma Technology LTD.Industry
NCT06506591 · 106 participants · Start Oct 26, 2023 · Primary completion Aug 15, 2024
Drug: WD-890; WD-890 Tablets Placebo · For: Healthy Participants
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z, Sun H, Wang Y, et al. · Biomed Pharmacother 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.